Cargando…

Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus

BACKGROUND: This study was performed to satisfy a US Food and Drug Administration post-marketing requirement to compare the dose responses for Technosphere(®) Insulin (TI; MannKind Corporation, Westlake Village, CA, USA) and subcutaneous insulin lispro (LIS) across a wide range of doses. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grant, Marshall, Heise, Tim, Baughman, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891188/ https://www.ncbi.nlm.nih.gov/pubmed/34773608 http://dx.doi.org/10.1007/s40262-021-01084-0

Ejemplares similares

Place of technosphere inhaled insulin in treatment of diabetes
por: Mikhail, Nasser
Publicado: (2016)

Hypoglycaemia is reduced with use of inhaled Technosphere(®) Insulin relative to insulin aspart in type 1 diabetes mellitus
por: Seaquist, E. R., et al.
Publicado: (2019)

Comprehensive Pulmonary Safety Review of Inhaled Technosphere(®) Insulin in Patients with Diabetes Mellitus
por: McGill, Janet B., et al.
Publicado: (2020)

A Population Dose–Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects
por: Rüppel, D, et al.
Publicado: (2017)

Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
por: Rosenstock, Julio, et al.
Publicado: (2008)

Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects
por: Shiramoto, Masanari, et al.
Publicado: (2022)

Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin
por: Bell, David S. H., et al.
Publicado: (2020)

Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin
por: Levin, Philip A, et al.
Publicado: (2016)

Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL
por: de la Peña, Amparo, et al.
Publicado: (2015)

Case of subcutaneous insulin resistance syndrome treated with ultra‐rapid insulin lispro
por: Ishii, Takahiro, et al.
Publicado: (2021)

A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes
por: Home, Philip, et al.
Publicado: (2018)

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator
por: Visentin, Roberto, et al.
Publicado: (2016)

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
por: Thrasher, James, et al.
Publicado: (2018)

Time–Action Profile of Technosphere Insulin in Children with Type 1 Diabetes
por: Haller, Michael J., et al.
Publicado: (2023)

Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin: Results of glucose clamp studies in youth with type 1 diabetes
por: Cengiz, Eda, et al.
Publicado: (2010)

Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study
por: Akturk, Halis Kaan, et al.
Publicado: (2018)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus
por: Candido, Riccardo, et al.
Publicado: (2018)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
por: Leohr, Jennifer, et al.
Publicado: (2020)

What is the value of faster acting prandial insulin? Focus on ultra rapid lispro
por: Heise, Tim, et al.
Publicado: (2022)

Ultra‐Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog(®) in Japanese patients with type 1 diabetes
por: Shiramoto, Masanari, et al.
Publicado: (2020)

Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO‐Pump‐2
por: Warren, Mark, et al.
Publicado: (2021)

Comparison of Insulin Lispro Protamine Suspension with NPH Insulin in Pregnant Women with Type 2 and Gestational Diabetes Mellitus: Maternal and Perinatal Outcomes
por: Colatrella, Antonietta, et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus
por: Heise, Tim, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus
por: Heise, Tim, et al.
Publicado: (2016)

Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes: A randomized open parallel multicenter study
por: Bolli, Geremia B., et al.
Publicado: (2009)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes
por: Heise, Tim, et al.
Publicado: (2016)

Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences
por: Haahr, Hanne, et al.
Publicado: (2019)

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
por: Kapitza, Christoph, et al.
Publicado: (2010)

Efficacy of insulin lispro in improving glycemic control in gestational diabetes
por: Deepaklal, M.C., et al.
Publicado: (2014)

Lispro insulin and electrolyte supplementation for treatment of diabetic ketoacidosis in cats
por: Anderson, Jodie D., et al.
Publicado: (2019)

Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus
por: Morello, Candis M
Publicado: (2011)

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
por: Leohr, Jennifer, et al.
Publicado: (2021)

Impact of diet on the efficacy of insulin lispro mix 25 and insulin lispro mix 50 as starter insulin in East Asian patients with type 2 diabetes: Subgroup analysis of the Comparison Between Low Mixed Insulin and Mid Mixed Insulin as Starter Insulin For Patients with Type 2 Diabetes Mellitus (CLASSIFY Study) randomized trial
por: Chen, Wei, et al.
Publicado: (2016)

Use of Insulin Lispro Protamine Suspension in Pregnancy
por: Lapolla, Annunziata, et al.
Publicado: (2015)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Comparison of thrice‐daily lispro 50/50 vs thrice‐daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes
por: Yamashiro, Keiko, et al.
Publicado: (2010)

Protocol to Assess the Biological Activity of Insulin Glargine, Insulin Lispro, and Insulin Aspart In Vitro
por: Garige, Mamatha, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gpipnk4ld34lvt1fgu8h8qu1rs